<DOC>
	<DOCNO>NCT02630277</DOCNO>
	<brief_summary>To assess safety efficacy intravitreal aflibercept injection regression retinal neovascularization secondary high-risk PDR . To characterize baseline/post-induction/maintenance level proinflammatory mediator patient high-risk PDR</brief_summary>
	<brief_title>Evaluation Treatment High riSk proLiferative Diabetic retinopathY With Intravitreal Aflibercept injectioN</brief_title>
	<detailed_description>This study evaluate two dose regimen ( monthly PRN follow load dose ) treatment PDR intravitreal aflibercept injection . Additionally , study identify biomarker mediator vitreous fluid present baseline patient PDR track course year profile change response two dosing regimen . The treatment regimens provide information biomarker profile monthly regimen well variable regimen . Furthermore , biomarker mediator may associate anti-VEGF responder non-responders may also identify . 105 biomarker mediator ( cytokines/chemokines ) identify play role PDR publish study profile patient PDR .</detailed_description>
	<mesh_term>Retinal Diseases</mesh_term>
	<mesh_term>Diabetic Retinopathy</mesh_term>
	<criteria>1 . Eligible eye active PDR high risk characteristic ( HRC ) define DRS . All eye must meet least one follow criterion : Any neovascularization disc ( NVD ) + vitreous hemorrhage Mild neovascularization disc ( NVD ) least 1/2 1/3 disc area show standard photograph 10A DRS Moderate neovascularization retina elsewhere ( NVE ) least 1/2 disc area show standard photograph 7 DRS + vitreous hemorrhage2 . Patient 's study eye must treatment naïve ; history intravitreal antiangiogenic treatment , intravitreal steroid treatment , laser treatment study eye 2 . 18 year old male female history diabetes mellitus ability sign inform consent 3 . ETDRS visual acuity score great equal 24 letter ( approximately 20/320 ) less equal 85 letter ( approximately 20/20 ) ETDRS visual acuity protocol screen visit 4 . Eyes mild preretinal hemorrhage mild vitreous hemorrhage interfere clear visualization macula optic disc eligible study Subjects meet follow criterion exclude study : 1 . Presence moderate dense PRH VH prevents clear visualization macula and/or optic disc 2 . Presence either : Significant epiretinal membrane involve macula , Proliferative diabetic membrane along major retinal arcade extensive enough cause either : Significant vitreomacular traction Significant impairment visual acuity Presence tractional retinal detachment Severe ischemia involve foveal avascular zone ( ≥1 disc area ) determine fluorescein angiography perform initial screen visit Significant medium opacity ( due cornea , anterior chamber , lens ) preclude clear visualization macula optic disc Presence neovascular glaucoma without hyphema Previous treatment intravitreal steroid injection study eye Previous treatment topical antiinflammatory medication study eye Previous treatment peribulbar steroid injection study eye Previous PRP/focal laser treatment study eye History vitreoretinal surgery study eye Previous treatment antiangiogenic drug either eye History idiopathic autoimmune uveitis either eye Active ocular inflammation ( include trace ) study eye Structural damage center macula study eye likely preclude improvement VA follow resolution macular edema , include atrophy retinal pigment epithelium , subretinal fibrosis , organize hardexudate plaque Ocular disorder study eye may confound interpretation study result , include retinal vascular occlusion , retinal detachment , macular hole , CNVM cause Concurrent disease study eye would compromise VA require medical surgical intervention study period Cataract surgery study eye , yttriumaluminumgarnet ( YAG ) laser capsulotomy , intraocular surgery Aphakia absence posterior capsule study Uncontrolled glaucoma previous filtration surgery study eye Evidence examination infectious blepharitis , keratitis , scleritis conjunctivitis either eye current treatment serious systemic infection History cerebral vascular accident myocardial infarction within 3 month prior Day 1 Participation investigational trial within 30 day prior screen involve treatment drug ( exclude vitamin mineral ) device Pregnancy ( positive pregnancy test ) lactation Sexually active men* woman childbearing potential** unwilling practice adequate contraception study ( adequate contraceptive measure include stable use oral contraceptive prescription pharmaceutical contraceptive 2 menstrual cycle prior screen ; intrauterine device [ IUD ] ; bilateral tubal ligation ; vasectomy ; condom plus contraceptive sponge , foam , jelly , diaphragm plus contraceptive sponge , foam , jelly )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Proliferative Diabetic Retinopathy</keyword>
	<keyword>High Risk PDR</keyword>
	<keyword>aflibercept</keyword>
	<keyword>regression retinal neovascularization</keyword>
</DOC>